

# DRIVE-AB: Driving Re-Investment in R&D and Responsible Antibiotic Use

## Creating, Testing and Validating New Economic Models for Antibiotic R&D

Christine Årdal

Norwegian Institute of Public Health

June 18, 2015

# Our aim

## FINANCIAL TIMES

May 14, 2015 6:09 pm

### New drugs way to avoid an antibiotic apocalypse

Share Author alerts Print Clip Gift Article Comments

Pharmaceutical industry needs incentives to overcome market failure



will be on the agenda of the World next month.

“The O’Neill proposals are still rudimentary but they represent the **best starting point** so far in developing new weapons to see off the threatened antibiotic apocalypse. Governments, health agencies and the pharmaceuticals industry should now engage seriously in drawing up a **detailed, practical plan** to put them into effect.”

# DRIVE-AB objective

To explore novel economic strategies and reward models both to promote the development of new antibiotics and to bolster appropriate consumption of existing antibiotics


- 3-year project (Oct 2014 – Sept 2017)
- Total project financing €10.8m (\$12m)
- 16 public and 7 private partners from 12 countries

# New Drugs 4 Bad Bugs (ND4BB)



Innovative Medicines Initiative

## Cross-project communication & collaboration



## ND4BB Information Centre

All data generated is submitted and made accessible to all partners

Ongoing projects


Projects under development



# Testing a new economic model

## Example – AMR Review’s hybrid model

- Coordinated by a single global body
- Giving a lump sum payment (US \$1 - 1.3 billion per antibiotic) to a company with a new worthy antibiotic
- Allowing freedom to sell the drugs for profit



# Testing a model

**1** Fit high-level parameters? Mitigate a bottleneck?

**2** How to pair with responsible use and availability?

**3** Will it stimulate action? By whom? Cost/benefit?

**4** How can it be implemented?

# 1

## Fit high-level parameters? Mitigate a bottleneck?

THE WALL STREET JOURNAL

Home World U.S. Politics Economy Business Tech Markets Opinion Arts Life

WORLD

### U.S. to Give \$1 Billion to Fund Immunizations

Donation Marks Increase in Funds to End Preventable Child Deaths in Developing World

By **BETSY MCKAY**

5 COMMENTS

Updated Jan. 26, 2015 5:24 p.m. ET

The U.S. government plans to donate \$1 billion over the next four years to GAVI, the Vaccine Alliance, to fund immunizations for millions of children in developing countries.


Sustainable?

The U.S. is increasing its contribution to international immunization efforts led by the GAVI partnership, but this latest pledge, for 2015 through 2018, is up from \$250 million a year. The previous U.S. donation, made in 2011, was for \$450 million over three years, or \$150 million a year.

The increase in funds reflects a global health priority for the administration of President Barack Obama and the growing number and cost of vaccines to combat the biggest child

# 2

## How to pair with responsible use and availability?




Prescriptions per 1,000 people



Source: CDDEP


3

Will it stimulate action? By whom? Cost/benefit?



# 4

## How can it be implemented?



# Validation

## Stakeholder platform

- Policymakers
- Patient groups
- Payers
- Regulatory authorities
- Health technology assessors
- Small and medium-sized enterprises
- EFPIA partners
- Venture capital firms
- Professional societies
- Civil society and global health groups

# Thank you!